Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp has a negative equity position of -3,157,950 CAD and a debt-to-equity ratio of -0.71, indicating a significant reliance on debt financing and a weak capital structure. The company's liquidity is further constrained by a current ratio of 0.23, suggesting limited ability to meet short-term obligations. Operating cash flow is negative at -2,294,990 CAD, and free cash flow is also negative at -1,846,870 CAD, highlighting a lack of cash generation from operations. Profitability metrics show a return on equity of 0.6505, which is unusually high given the negative equity position, and a return on assets of -1.0896, indicating that the company is not generating returns from its asset base. Gross profit of 104,790 CAD is significantly lower than the company's operating and net losses of -2,054,120 CAD, suggesting high operating costs and inefficiencies. The company's revenue of 192,650 CAD is derived from undisclosed segments and geographic regions, as no specific breakdown is provided in the available data. There is no information on revenue concentration or geographic exposure, making it difficult to assess the company's diversification and risk profile. The company's growth trajectory is unclear, as there are no forward-looking revenue or earnings estimates provided in the available data. Historical revenue of 192,650 CAD and a net loss of -2,054,120 CAD suggest a challenging operating environment and potential financial distress. Risk factors include a medium liquidity risk due to negative net cash and a high debt burden, as well as a low dilution risk based on the current share structure. The company's negative equity and high debt levels may limit its ability to raise additional capital without dilution. Recent events include the disclosure of a last actual EPS of -0.10 CAD and a last actual revenue of 101,000 CAD, indicating continued financial underperformance. No recent filings or transcripts are available to provide further insight into the company's operations or strategic direction.
Business. Rapid Dose Therapeutics Corp is a medical equipment and supplies company that provides healthcare services and equipment, primarily generating revenue through product sales and service offerings.
Classification. Rapid Dose Therapeutics Corp is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a classification confidence of 0.92.
- Rapid Dose Therapeutics Corp has a negative equity position and a high debt burden, indicating significant financial distress.
- The company's liquidity is constrained, with a current ratio of 0.23 and negative operating and free cash flows.
- Profitability is weak, with a negative return on assets and a high operating loss relative to gross profit.
- Revenue and segment details are not disclosed, limiting the ability to assess diversification and growth potential.
- The company's financial performance suggests a challenging operating environment and potential for further losses.
- # RATIONALES
- {
- "margin_outlook_rationale": "The company's margin outlook is negative due to high operating costs and a significant operating loss relative to gross profit.",
- Net cash is negative after subtracting total debt.